Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

National Cancer Institute (NCI) is the lead sponsor of 4 current clinical trials in our Ireland register. None of its ClinicalTrials.gov trials is recruiting at the moment. All registered phases are Phase 3. The drugs named most often in its trials are Anastrozole, Exemestane and Letrozole. The most-studied condition is Light Chain Deposition Disease.

ClinicalTrials.gov trials by status

Active, closed4100%

Trials by phase

Phase 34100%

Clinical trials sponsored by National Cancer Institute (NCI)

4 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma NCT01169337 · Light Chain Deposition Disease, Smoldering Multiple Myeloma Drug: Lenalidomide	Phase 3	Active, closed	2011-01	Ireland
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery NCT02506153 · ClinicalTrials.gov ↗ · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma Drugs: Ipilimumab, Pembrolizumab	Phase 3	Active, closed	2015-11	Ireland
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) NCT00310180 · ClinicalTrials.gov ↗ · Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7 Drugs: Anastrozole, Exemestane, Letrozole	Phase 3	Active, closed	2006-04	Ireland
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer NCT01272037 · ClinicalTrials.gov ↗ · Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma Drugs: Anastrozole, Exemestane, Letrozole	Phase 3	Active, closed	2011-02	Ireland

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in National Cancer Institute (NCI) trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Anastrozole2 Exemestane2 Letrozole2 Tamoxifen Citrate2 Ipilimumab1 Lenalidomide1 Pembrolizumab1

Conditions in National Cancer Institute (NCI) trials

14 conditions

Light Chain Deposition Disease1Smoldering Multiple Myeloma1Clinical Stage III Cutaneous Melanoma AJCC v81Clinical Stage IV Cutaneous Melanoma AJCC v81Metastatic Cutaneous Melanoma1Metastatic Mucosal Melanoma1Breast Adenocarcinoma1Hormone Receptor Positive1Stage IA Breast Cancer AJCC v71Stage IB Breast Cancer AJCC v71Breast Ductal Carcinoma In Situ1Invasive Breast Carcinoma1Multicentric Breast Carcinoma1Multifocal Breast Carcinoma1

By trial register

Register	Trials	Recruiting
Clinical trials in Ireland	4	0

A trial with sites in more than one country appears in each of those registers.

Questions about National Cancer Institute (NCI) trials

How many clinical trials does National Cancer Institute (NCI) sponsor?

National Cancer Institute (NCI) is the lead sponsor of 4 current trials on ClinicalTrials.gov in our Ireland register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are National Cancer Institute (NCI) trials recruiting?

Not at the moment. None of its 4 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Which drugs is National Cancer Institute (NCI) testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are Anastrozole (2), Exemestane (2), Letrozole (2), Tamoxifen Citrate (2) and Ipilimumab (1). The number in brackets is how many of its trials name each drug.

Does National Cancer Institute (NCI) have clinical trials in Ireland?

Yes. 4 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

National Cancer Institute (NCI) clinical trials